

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Clevor 30 mg/ml eye drops, solution in single-dose container for dogs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml of solution contains:

Active substance:

Ropinirole (ropinirol) 30 mg
(equivalent to 34.2 mg ropinirole hydrochloride)

Excipients:

Qualitative composition of excipients and other constituents
Citric acid monohydrate
Sodium citrate
Sodium chloride
Sodium hydroxide (to adjust pH)
Hydrochloric acid (to adjust pH)
Water for injections

Very slightly yellow to yellow clear solution.

3. CLINICAL INFORMATION

3.1 Target species

Dogs

3.2 Indications for use for each target species

Induction of vomiting in dogs.

3.3 Contraindications

Do not use in dogs with depression of the central nervous system, seizures or other marked neurologic impairments that could lead to aspiration pneumonia.

Do not use in dogs which are hypoxic, dyspnoeic or lacking pharyngeal reflexes.

Do not use in cases of the ingestion of sharp foreign objects, corrosive agents (acids or alkalis), volatile substances or organic solvents.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

3.4 Special warnings

The efficacy of the veterinary medicinal product has not been established in dogs weighing less than 1.8 kg, or in dogs under 4.5 months of age or in elderly dogs. Use only according to the benefit-risk assessment by the responsible veterinarian.

Based on the clinical trial results, most dogs are expected to respond to a single dose of the veterinary medicinal product; however, a small proportion of dogs will require a second dose to induce vomiting. A very small proportion of dogs may fail to respond to the treatment despite administration of a

second dose. It is not recommended to administer further doses to these dogs. Please refer to sections 3.9 and 4.2 for further information.

3.5 Special precautions for use

Special precautions for safe use in the target species:

This veterinary medicinal product may cause a transient increase in heart rate up to 2 hours after administration. The safety of the veterinary medicinal product has not been studied in dogs with diagnosed cardiac disease/dysfunction. Use only according to the benefit-risk assessment by the responsible veterinarian.

The safety of this veterinary medicinal product in dogs with clinical signs due to the ingestion of foreign materials has not been investigated.

Ropinirole is metabolised by the liver. The safety of the veterinary medicinal product has not been studied in dogs with hepatic impairment. Use only according to the benefit-risk assessment by the responsible veterinarian.

The safety and efficacy of the veterinary medicinal product have not been studied in dogs with ocular disease or injury. In case of a pre-existing ocular condition with clinical signs, use the veterinary medicinal product only according to the benefit-risk assessment by the responsible veterinarian.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to ropinirole should avoid contact with the veterinary medicinal product. Administer the veterinary medicinal product with caution.

The veterinary medicinal product should not be administered by pregnant or breast-feeding women. Ropinirole might reduce the level of prolactin due to its inhibitory effect on prolactin secretion as a dopamine agonist.

This veterinary medicinal product can cause eye irritation. Administer the veterinary medicinal product with caution. In case of accidental eye or skin contact, rinse immediately the affected area with plenty of fresh water. If symptoms occur, seek medical advice and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Dogs:

Very common (> 1 animal / 10 animals treated):	Increased heart rate ¹ Eye redness ² , Ocular discharge ² , Third eyelid protrusion ² , Blepharospasm ² Lethargy ¹
Common (1 to 10 animals / 100 animals treated):	Vomiting ³ , Diarrhoea ¹ Conjunctival oedema ¹ , Eye itching ¹

	Ataxia ¹ , Incoordination ¹ , Tremor ¹ Tachypnoea ¹
Uncommon (1 to 10 animals / 1 000 animals treated):	Corneal ulcer

¹Transient mild

²Transient mild or moderate

³Extended vomiting (for more than 60 minutes) should be evaluated by the responsible veterinarian as it might need appropriate treatment.

In dogs with extended vomiting and other clinical signs related to the pharmacological action of the active substance (e.g. eye redness, increased heart rate or tremor), dopamine antagonists such as metoclopramide or domperidone may be used to manage these clinical signs.

Maropitant does not reverse the clinical signs related to the pharmacological action of ropinirole.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy and lactation in the target species. Ropinirole inhibits prolactin secretion by activation of dopamine D₂ receptors located in the striatum and on lactotroph cells of pituitary gland. Therefore, use of this veterinary medicinal product is not recommended during pregnancy or lactation.

3.8 Interaction with other medicinal products and other forms of interaction

Dopamine antagonists (such as metoclopramide), neuroleptics (e.g., chlorpromazine, acepromazine) and other medicinal products with antiemetic properties (e.g., maropitant or antihistamines) may reduce the effectiveness of this veterinary medicinal product.

3.9 Administration routes and dosage

Ocular use.

The veterinary medicinal product is to be administered into the eye, at a dose of 1–8 eye drops. The volume of one drop is approximately 27 µl. Each eye drop contains 810 mcg of ropinirole. The dose is equivalent to 2–15 µl/kg bodyweight (bw) in dogs. The number of eye drops in each body weight group corresponds to the target dose of 3.75 mg/m² body surface area (dose range 2.7–5.4 mg/m²). These doses have been tested in dogs weighing between 1.8 kg and 100 kg (0.15–2.21 m² body surface area).

When a quantity of 2 to 4 drops is to be administered, the dose should be divided between both eyes. For example, for the administration of 3 drops: administer 2 drops into the right eye and 1 drop into the left eye.

When a quantity of 6 or 8 drops is to be administered, the dose should be divided into 2 alternate administrations given 1–2 minutes apart. For example, for the administration of 6 drops: administer 2 drops into the right eye and 2 drops into the left eye, then after 1–2 minutes pause, administer a further 1 drop into each eye.

If the dog does not vomit within 15 minutes after administration of the initial dose a second dose may be given 15 to 20 minutes after administration of the initial dose. The second dose should be the same number of drops as the initial dose. It is recommended to record the time of first administration.

Be careful not to touch the dropper tip after opening the container in case a second dose is necessary.

The following dosing table provides the dose in drops to be administered corresponding to the dog's bodyweight.

Body weight (kg)	Body surface area (m ²)	Number of eye drops	Ropinirole (mcg)	Ropinirole (mg/m ² body surface area)	Ropinirole (mcg/kg)
1.8–5	0.15–0.30	1	810	5.4–2.7	450–162
5.1–10	0.30–0.47	2	1620	5.4–3.4	318–162
10.1–20	0.48–0.75	3	2430	5.1–3.2	240–121
20.1–35	0.75–1.09	4	3240	4.3–3.0	161–93
35.1–60	1.10–1.57	6	4860	4.4–3.1	138–81
60.1–100	1.57–2.21	8	6480	4.1–2.9	108–64.5

Instructions for use



OPENING THE CONTAINER:

Open the container by twisting off the tail.

Be careful not to touch the dropper tip after opening the container.



ADMINISTRATION:

Keep the dog's head steady in a slightly upright position. Hold the container in an upright position without touching the eye. Rest your little finger on the forehead of the dog to maintain the distance between the container and the eye. Squeeze the prescribed number of drops into the eye(s).



STORING THE OPENED CONTAINER:

After opening place the container back into the pouch in case a second dose is necessary.



REPEATED DOSE:

In case the dog does not vomit within 15 minutes after the initial administration, a second dose can be given 15 to 20 minutes after administration of the initial dose. The additional dose should be the same as the initial dose.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

The tolerance of this veterinary medicinal product was investigated in a target animal safety study at all dose levels up to 5 times the clinical dose (that is, up to 124.6 µl/kg) when given on two occasions, 15–20 minutes apart, every day for 3 days. The clinical signs (lethargy, tachycardia, tremor, ataxia, incoordination, hyperaemia of the eye, ocular discharge, protrusion of the 3rd eyelid and blepharospasm) were comparable in frequency and severity between the different dose groups. Increased mean heart rate was observed one hour after treatment with all three doses (1X, 3X, 5X) and went back to normal levels after 6 hours.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

The veterinary medicinal product should only be administered by a veterinarian or under their close supervision.

3.12 Withdrawal periods

Not applicable.

4. PHARMACOLOGICAL INFORMATION

4.1 ATCvet code: QN04BC04

4.2 Pharmacodynamics

Ropinirole is a full dopamine agonist with high selectivity for the dopamine D₂-like receptor family (D₂, D₃ and D₄ receptors). It induces emesis by activating the D₂-like receptors in the chemoreceptor trigger zone, located in the area postrema, which transmits the information to the emesis centre to trigger vomiting. In a clinical field trial including 100 clinically healthy dogs treated with Clevor, the time from administration to first vomit was 3–37 minutes with a mean time of 12 minutes and median time of 10 minutes. The time between the first to the last vomit was 0–108 minutes (0 if the dog vomited only once) with a mean duration of 23 minutes and a median duration of 16 minutes. Within 30 minutes 95 % of the dogs vomited. An additional dose was administered after 20 minutes to 13 % of the dogs because of lack of efficacy. Three dogs (3 %) did not vomit at all despite an additional dose. 5 % of the dogs in the clinical study received anti-emetic treatment (metoclopramide) because their vomiting persisted for more than 60 minutes.

4.3 Pharmacokinetics

Absorption

Ropinirole is rapidly absorbed into the systemic circulation of dogs after administration as a solution on their eye surface. At the target dose of 3.75 mg/m² (equivalent to 2–15 µl/kg bw), a peak plasma concentration (C_{max}) of 26 ng/ml is reached 10 to 20 minutes (t_{max}) after administration. The systemic bioavailability of the veterinary medicinal product by this ocular route of administration is 23 %. Vomiting starts before the C_{max} in plasma is reached; at 4–6 minutes in a pharmacokinetic study in dogs. No direct correlation between ropinirole concentration in plasma and the duration of vomiting was observed after ocular administration. The time to last vomit ranged from 30 to 82 minutes following ocular administration in a pharmacokinetic study in dogs.

Distribution

Ropinirole is rapidly distributed and has a relatively high apparent volume of distribution. In dogs, the volume of distribution (V_z) is 5.6 l/kg after intravenous administration. The fraction bound to plasma proteins in dogs is low (37 %).

Elimination

Ropinirole is mainly eliminated by hepatic metabolism. The half-life of elimination ($t_{1/2}$) is 4 hours after intravenous administration to dogs. Biotransformation occurs by dealkylation, hydroxylation and subsequent conjugation with glucuronic acid or oxidation to carboxylic acid. About 40 % of radioactive ropinirole is excreted in the urine within 24 hours after intravenous administration to dogs. Excretion in the urine occurs mainly as metabolites. The portion recovered as unchanged ropinirole in the urine is below 3 % within the first 24 hours.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Not applicable.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 30 months.

Shelf life after first opening the immediate packaging (pouch and container): 30 minutes.

5.3 Special precautions for storage

This veterinary medicinal product does not require any special temperature storage conditions. Store the container in the pouch in order to protect from light.

After opening the pouch, the container should be kept in the pouch to protect from light. Discard any opened individual pouch or container with any remaining liquid after 30 minutes.

5.4 Nature and composition of immediate packaging

Low density polyethylene plastic single-dose container containing 0.6 ml.

Each plastic container is packed in an individual aluminium foil laminate pouch. The pouch/pouches are then packed in a cardboard box together with the same number of package leaflets (intended for the animal owners) as the number of single-dose containers in the outer package.

Pack sizes: 1, 2, 3, 4, 5, 6, 8 and 10 single-dose containers.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Orion Corporation

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/17/222/001 – 1 single-dose container
EU/2/17/222/002 – 2 single-dose containers
EU/2/17/222/003 – 4 single-dose containers
EU/2/17/222/004 – 5 single-dose containers
EU/2/17/222/005 – 6 single-dose containers
EU/2/17/222/006 – 8 single-dose containers
EU/2/17/222/007 – 10 single-dose containers
EU/2/17/222/008 – 3 single-dose containers

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 13/04/2018

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE**Cardboard box****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Clevor 30 mg/ml eye drops, solution

2. STATEMENT OF ACTIVE SUBSTANCES

1 ml contains: 30 mg ropinirole.

3. PACKAGE SIZE

1 x 0.6 ml single-dose container
2 x 0.6 ml single-dose containers
3 x 0.6 ml single-dose containers
4 x 0.6 ml single-dose containers
5 x 0.6 ml single-dose containers
6 x 0.6 ml single-dose containers
8 x 0.6 ml single-dose containers
10 x 0.6 ml single-dose containers

4. TARGET SPECIES

Dogs

**5. INDICATIONS****6. ROUTES OF ADMINISTRATION**

Ocular use.

7. WITHDRAWAL PERIODS**8. EXPIRY DATE**

Exp. {mm/yyyy}
Once opened use within 30 minutes.

9. SPECIAL STORAGE PRECAUTIONS

Store the container in the pouch in order to protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”
--

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”
--

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
--

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Orion Corporation

14. MARKETING AUTHORISATION NUMBERS
--

EU/2/17/222/001 – 1 single-dose container
EU/2/17/222/002 – 2 single-dose containers
EU/2/17/222/003 – 4 single-dose containers
EU/2/17/222/004 – 5 single-dose containers
EU/2/17/222/005 – 6 single-dose containers
EU/2/17/222/006 – 8 single-dose containers
EU/2/17/222/007 – 10 single-dose containers
EU/2/17/222/008 – 3 single-dose containers

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**Pouch label****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Clevor 30 mg/ml eye drops, solution

2. STATEMENT OF ACTIVE SUBSTANCES

30 mg/ml ropinirole

3. TARGET SPECIES

Dogs

**4. ROUTES OF ADMINISTRATION**

Ocular use.

Read the package leaflet before use.

5. WITHDRAWAL PERIODS**6. EXPIRY DATE**

Exp. {mm/yyyy}

Once opened use within 30 minutes.

7. SPECIAL STORAGE PRECAUTIONS

Store the container in the pouch in order to protect from light.

8. NAME OF THE MARKETING AUTHORISATION HOLDER

Orion Corporation

9. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Single-dose container label

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
--

Clevor



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

30 mg/ml

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Clevor 30 mg/ml eye drops, solution in single-dose container for dogs

2. Composition

Each ml contains:

Active substance:

Ropinirole (ropinirol) 30 mg
(equivalent to 34.2 mg ropinirole hydrochloride)

This veterinary medicinal product is a very slightly yellow to yellow clear solution.

3. Target species

Dogs



4. Indications for use

For induction of vomiting in dogs.

5. Contraindications

Your dog must not be given this medicine if it:

- has decreased consciousness, seizures or other similar neurologic symptoms or difficulties in breathing or swallowing that could make the dog inhale a part of the vomit potentially causing aspiration pneumonia
- has ingested sharp foreign objects, acids or alkalis (e.g. drain or toilet bowl cleaners, household detergents, battery fluids), volatile substances (e.g. petroleum products, essential oils, air fresheners) or organic solvents (e.g. antifreeze, windshield wiper fluids, nail polish remover)
- is hypersensitive to ropinirole or to any of the excipients.

6. Special warnings

Special precautions for safe use in the target species:

The efficacy of the veterinary medicinal product has not been established in dogs weighing less than 1.8 kg, or in dogs under 4.5 months of age or in elderly dogs. Use only according to the benefit-risk assessment by the responsible veterinarian.

This veterinary medicinal product may cause a transient increase in heart rate up to 2 hours after administration. The safety of the veterinary medicinal product has not been studied in dogs with

diagnosed cardiac disease/dysfunction. Use only according to the benefit-risk assessment by the responsible veterinarian.

The safety of this veterinary medicinal product in dogs with clinical signs due to the ingestion of foreign materials has not been investigated.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to ropinirole should avoid contact with the veterinary medicinal product. Administer the veterinary medicinal product with caution.

The veterinary medicinal product should not be administered by pregnant or breast-feeding women. Ropinirole might reduce the level of prolactin, a hormone that stimulates milk production in pregnant or breast-feeding women.

This veterinary medicinal product can cause eye irritation. Administer the veterinary medicinal product with caution. In case of accidental eye or skin contact, rinse immediately the affected area with plenty of fresh water. If symptoms occur, seek medical advice and show the package leaflet or the label to the physician.

Pregnancy and lactation:

The safety of this veterinary medicinal product has not been established during pregnancy and lactation in the target species. Ropinirole might reduce the level of prolactin, a hormone that stimulates milk production in pregnant or suckling females. Therefore, use of the veterinary medicinal product is not recommended during pregnancy or lactation.

Interaction with other medicinal products and other forms of interaction:

Inform your veterinarian if your dog is given other medicines.

Other medicines that have antiemetic properties, such as metoclopramide, chlorpromazine, acepromazine, maropitant or antihistamines may diminish the effectiveness of ropinirole.

Overdose:

The tolerance of this veterinary medicinal product has been tested in dogs up to 5 times the recommended dose. Symptoms of overdose consist of the same signs seen as adverse reactions.

If vomiting or some of the adverse reactions (e.g. redness of the eye, increased heart rate or shivering) are prolonged, contact your veterinarian. The effects of ropinirole can be reversed using a specific antidote such as metoclopramide or domperidone. Maropitant does not reverse the clinical signs related to the pharmacological action of ropinirole.

7. Adverse events

This veterinary medicinal product may cause the following adverse reactions:

Dogs:

Very common (> 1 animal / 10 animals treated):	Increased heart rate ¹ Eye redness ² , Ocular discharge ² , Third eyelid protrusion ² , Blepharospasm ²
---	---

	Lethargy ¹
Common (1 to 10 animals / 100 animals treated):	Vomiting ³ , Diarrhoea ¹ Conjunctival oedema ¹ , Eye itching ¹ Ataxia ¹ , Incoordination ¹ , Tremor ¹ Tachypnoea ¹
Uncommon (1 to 10 animals / 1 000 animals treated):	Corneal ulcer

¹Transient mild

²Transient mild or moderate

³Extended vomiting (for more than 60 minutes) should be evaluated by the responsible veterinarian as it might need appropriate treatment.

In dogs with extended vomiting and other clinical signs related to the pharmacological action of the active substance (e.g. eye redness, increased heart rate or, tremor), dopamine antagonists such as metoclopramide or domperidone may be used to manage these clinical signs.

Maropitant does not reverse the clinical signs related to the pharmacological action of ropinirole.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

8. Dosage for each species, routes and method of administration

Clevor is administered as eye drops into one or both of the dog's eyes at a dose of 1–8 eye drops, depending on the dog's bodyweight. If the dog does not vomit within 15 minutes after administration of the initial dose, a second dose may be given 15 to 20 minutes after administration of the initial dose. The second dose should be the same number of drops as the initial dose. It is recommended to record the time of first administration.

Be careful not to touch the dropper tip after opening the container in case a second dose is necessary.

The following dosing table provides the dose volume in drops to be administered corresponding to the dog's bodyweight.

When a quantity of 2 to 4 drops is to be administered, the dose should be divided between both eyes. For example, for the administration of 3 drops: administer 2 drops into the right eye and 1 drop into the left eye.

When a quantity of 6 or 8 drops is to be administered, the dose should be divided into 2 alternate administrations given 1–2 minutes apart. For example, for the administration of 6 drops: administer 2 drops into the right eye and 2 drops into the left eye, then after 1–2 minutes pause administer a further 1 drop into each eye.

Dog bodyweight (kg)	Number of eye drops
1.8–5	1
5.1–10	2
10.1–20	3

20.1–35	4
35.1–60	6
60.1–100	8

9. Advice on correct administration

The veterinary medicinal product should only be administered by a veterinarian or under their close supervision.

See the detailed instructions for administration at the end of this leaflet.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

This veterinary medicinal product does not require any special temperature storage conditions. Store the container in the pouch in order to protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label or carton after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging (pouch and container): 30 minutes.
After opening the pouch, the container should be kept in the pouch to protect from light.
Discard any opened individual pouch or container with any remaining liquid after 30 minutes.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/17/222/001 – 1 single-dose container
EU/2/17/222/002 – 2 single-dose containers
EU/2/17/222/003 – 4 single-dose containers
EU/2/17/222/004 – 5 single-dose containers
EU/2/17/222/005 – 6 single-dose containers
EU/2/17/222/006 – 8 single-dose containers
EU/2/17/222/007 – 10 single-dose containers

EU/2/17/222/008 – 3 single-dose containers

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder:

Orion Corporation
Orionintie 1
FI-02200 Espoo
Finland

Manufacturer responsible for batch release:

Orion Corporation Orion Pharma
Orionintie 1
FI-02200 Espoo
Finland

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

Ecuphar NV
Legeweg 157-i, B-8020 Oostkamp, Belgique
Tel: + 32 50 31 42 69

Lietuva

UAB „ORION PHARMA“
Ukmergės g. 126
LT-08100 Vilnius, Lietuva
Tel: +370 5 2769 499

Република България

Вет-трейд ООД
бул. България 1
6000 Стара Загора, България
Тел: + 359 42 636 858

Luxembourg/Luxemburg

Ecuphar SA
Legeweg 157-i, B-8020 Oostkamp, Belgique
Tel: + 32 50 31 42 69

Česká republika

Orion Pharma s.r.o.
Na Strži 2102/61a,
Praha, 140 00
Tel: +420 227 027 263

Magyarország

Orion Pharma Kft.
1139 Budapest, Pap Károly u. 4-6
Tel.: +36 1 2370603

Danmark

Orion Pharma A/S,
Ørestads Boulevard 73,
2300 København S
Tlf: +45 86 14 00 00

Malta

Orion Corporation
Orionintie 1, FI-02200 Espoo
Finland
Tel: + 358 10 4261

Deutschland

Ecuphar GmbH
Brandteichstraße 20, DE-17489 Greifswald

Nederland

Ecuphar BV
Verlengde Poolseweg 16, 4818 CL Breda, Nederland

Tel: + 49 (0)3834 835840

Eesti

UAB „ORION PHARMA“
Ukmergēs g. 126
LT-08100 Vilnius, Leedu
Tel: +370 5 2769 499

Ελλάδα

ΕΛΑΝΚΟ ΕΛΛΑΣ Α.Ε.Β.Ε.
Λεωφόρος Μεσογείων 335,
ΕΛ-152 31 Χαλάνδρι, Αττική
Τηλ.: +30 6946063971

España

Ecuphar Veterinaria S.L.U.
C/Cerdanya, 10-12 Planta 6º 08173 Sant Cugat
del Vallés Barcelona (España)
Tel. + 34 93 5955000

France

Axience
Tour Eссор - 14, rue Scandicci 93500 Pantin.
France.
Tel. +33 1 41 83 23 10

Hrvatska

Orion Corporation
Orionintie 1, FI-02200 Espoo
Finland
Tel: + 358 10 4261

Ireland

Duggan Veterinary Supplies Ltd
Holycross, County Tipperary
IE-J4QM+6G
Tel: +353 504 43169

Ísland

Orion Corporation
Orionintie 1, FI-02200 Espoo
Finland
Tel: + 358 10 4261

Italia

Ecuphar Italia S.r.l.
Viale Francesco Restelli, 3/7 20124 Milano
(Italia)
Tel: + 39 02 829 506 04

Tel: + 31 880033800

Norge

Orion Pharma AS Animal Health
Postboks 4366 Nydalen,
N-0402 Oslo
Tlf: +47 40 00 41 90

Österreich

VetViva Richter GmbH
Durisolstrasse 14, 4600 Wels,
Austria
Tel.: +43 664 8455326

Polska

Orion Pharma Poland Sp. z o.o.
ul. Fabryczna 5A,
00-446 Warszawa
Tel: +48 22 833 31 77

Portugal

Belphar, Lda.
Sintra Business Park, N°7, Edifício 1 -
Escritório 2K Zona Industrial de Abrunheira 2710-
089 Sintra. Portugal
Tel: + +351 308 808 321

România

Orion Pharma România srl
B-dul T. Vladimirescu nr 22,
București, 050883-RO
Tel: +40 31845 1646

Slovenija

IRIS d.o.o.
Cesta v Gorice 8
1000 Ljubljana
Tel: +386 (0)1 2006650

Slovenská republika

Orion Pharma s.r.o.
Na strži 2102/61a,
Praha, 140 00, ČR
Tel: +420 227 027 263

Suomi/Finland

ORION PHARMA Eläinlääkkeet
PL/PB 425,
FI-20101 Turku/Åbo
Puh/Tel: +358 10 4261

Κύπρος

ΕΛΑΝΚΟ ΕΛΛΑΣ Α.Ε.Β.Ε.
Λεωφόρος Μεσογείων 335,
ΕΛ-152 31 Χαλάνδρι, Αττική
Τηλ.: +30 6946063971

Sverige

Orion Pharma AB, Animal Health,
Golfvägen 2, SE-182 31 Danderyd
Tel: +46 8 623 64 40

Latvija

UAB „ORION PHARMA“
Ukmergės g. 126
LT-08100 Vilnius, Lietuva
Tel: +370 5 2769 499

United Kingdom (Northern Ireland)

Ecuphar NV
Legeweg 157-i, B-8020 Oostkamp, Belgium
Tel: + 32 50 31 42 69

17. Other information**Pharmacodynamic properties**

Ropinirole is a full dopamine agonist with high selectivity for the dopamine D₂-like receptor family (D₂, D₃ and D₄ receptors). It induces emesis by activating the D₂-like receptors in the chemoreceptor trigger zone, located in the area postrema, which transmits the information to the emesis centre to trigger vomiting. In a clinical field trial including 100 clinically healthy dogs treated with Clevor, the time from administration to first vomit was 3–37 minutes with a mean time of 12 minutes and median time of 10 minutes. The time between the first to the last vomit was 0–108 minutes (0 if the dog vomited only once) with a mean duration of 23 minutes and a median duration of 16 minutes. Within 30 minutes 95 % of the dogs vomited. An additional dose was administered after 20 minutes to 13 % of the dogs because of lack of efficacy. Three dogs (3 %) did not vomit at all despite an additional dose. 5 % of the dogs in the clinical study received anti-emetic treatment (metoclopramide) since their vomiting persisted for more than 60 minutes.

Clevor 30 mg/ml eye drops, solution is supplied in single-dose containers containing 0.6 ml. Each container is sealed in an individual aluminium foil laminate pouch. The pouches are further packed in outer cardboard cartons which contain 1, 2, 3, 4, 5, 6, 8 or 10 single-dose containers, together with the corresponding number of package leaflets.

Instructions for administration**OPENING THE CONTAINER:**

Open the container by twisting off the tail. Be careful not to touch the dropper tip after opening the container.

**ADMINISTRATION:**

Keep the dog's head steady in a slightly upright position. Hold the container in an upright position without touching the eye. Rest your little finger on the forehead of the dog to maintain the distance between the container and the eye. Squeeze the prescribed number of drops into the eye(s).

**STORING THE OPENED CONTAINER:**

After opening place the container back into the pouch, in case a second dose is necessary.

**REPEATED DOSE:**

In case the dog does not vomit within 15 minutes after the initial administration, a second dose can be given 15 to 20 minutes after administration of the initial dose. The additional dose should be the same as the initial dose.